Showing results (1-10 of 132) with videos related to
Sort By:
Pageof 14
Polskie Archiwum Medycyny Wewnetrznej|August 22, 2009
Therapeutic properties and safety of recombinant factor VIII and factor IXJoanna Zdziarska, Krzysztof Chojnowski, Anna Klukowska, et al.Polskie Archiwum Medycyny Wewnetrznej|September 10, 2008
[Antiphospholipid antibodies--risk factors for venous thromboembolism and arterial thrombosis]Krystyna ZawilskaPolskie Archiwum Medycyny Wewnetrznej|April 11, 2003
[Antiphospholipid antibodies as risk factor for venous thromboembolism]Jerzy WindygaSeminars in Thrombosis and Hemostasis|April 21, 2016
Is Continuous Low-Dose Prophylaxis Superior to On-Demand Treatment for Patients with Hemophilia?Jerzy WindygaPolskie Archiwum Medycyny Wewnetrznej|November 23, 2007
[Acquired haemophilia]Anna Buczma, Jerzy WindygaPolish Archives of Internal Medicine|April 8, 2025
Antithrombotic therapy in patients with inherited bleeding disorders: practical considerationsJerzy Windyga, Riitta LassilaPolskie Archiwum Medycyny Wewnetrznej|December 5, 2012
Therapeutic problems in elderly patients with hemophiliaKrystyna Zawilska, Maria Podolak-DawidziakPolskie Archiwum Medycyny Wewnetrznej|July 1, 2009
[Clinically asymptomatic antiphospholipid antibodies--diagnostic and therapeutic problems]Krystyna Zawilska, Agata Lehmann-KopydłowskaPolskie Archiwum Medycyny Wewnetrznej|February 17, 2006
[The role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in obesity]Edyta Kołacz, Krzysztof Lewandowski, Krystyna ZawilskaNeurologia I Neurochirurgia Polska|June 7, 2015
Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practiceMaria Łukasik, Krystyna Zawilska, Anetta UndasPageof 14